Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy

1Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China

2Department of Hematology, Xiangya Third Hospital, Central South University, Changsha, Hunan 410013, China

3Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China

4Department of Hematology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250063, China

5Institute of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China

6Peking University People's Hospital, Peking University Institute of Hematology, Beijing 100044, China

7Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, China

8Department of Hematology, Tongji Hospital of Tongji University, Shanghai 200092, China

9Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China

10Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

11Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China

12Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, China

13State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China

14Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221006, China

15Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China

16Department of Hematology, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, China

17Medical Center of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing 400037, China

18Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

19Molecular and Immunological Department, Chinese People's Liberation Army General Hospital, Beijing 100853, China

20Bio-Therapeutic Department, Chinese People's Liberation Army General Hospital, Beijing 100853, China

21Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.

Correspondence to: Dr. Yu Hu, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan, Hubei 430022, ChinaE-Mail: [email protected];Dr. Heng Mei, Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, ChinaE-Mail: [email protected];Dr. Weidong Han, Chinese People's Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100853, ChinaE-Mail: [email protected]

How to cite this article: Mei H, Chen F, Han Y, Hou M, Huang H, Huang X, Li Y, Liang A, Liu Q, Niu T, Peng J, Song WQ, Wang J, Wang Y, Wu D, Xu K, Yang L, Yang R, Zhang L, Zhang L, Zhang X, Zhang X, Zhao W, Han W, Hu Y. Chinese expert consensus on the management of chimeric antigen receptor T cell therapy-associated coagulopathy. Chin Med J 2022;135:1639–1641. doi: 10.1097/CM9.0000000000002288

Received 30 December, 2021

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.cmj.org).

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

留言 (0)

沒有登入
gif